GlassScriptPhysician profile
Eve Y Lupenko
NPI 1699749713
$24,353.92
in general payments reported to CMS, 2019-2025
45 companies · $7,413 in 2025
The $7,413 reported for 2025 was more than what 91% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,653 · 2020: $2,033 · 2021: $3,234 · 2022: $2,516 · 2023: $2,752 · 2024: $4,753 · 2025: $7,413.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,000 · Education: $426 · Consulting Fee: $350.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,142.18 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,000.00 |
| Education | $426.24 |
| Consulting Fee | $350.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Journey Medical Corporation | $3,445.41 | 2022-2025 | |
| Arcutis Biotherapeutics, INC. | $2,990.27 | 2023-2025 | Zoryve |
| Sun Pharmaceutical Industries INC. | $1,829.65 | 2019-2025 | Absorica Ld, Winlevi, Ilumya |
| Medimetriks Pharmaceuticals, INC. | $1,464.44 | 2019-2024 | Sumadan Wash, Ketodan, Neo-Synalar |
| Incyte Corporation | $1,426.50 | 2021-2025 | Opzelura, Opzelura |
| Galderma Laboratories, L.P. | $1,311.78 | 2019-2025 | Aklief, Nemluvio, Dysport |
| Mayne Pharma Commercial LLC | $1,182.19 | 2019-2025 | |
| Janssen Biotech, INC. | $1,088.35 | 2020-2025 | Tremfya, Stelara, Simponi |
| Dermavant Sciences, INC. | $929.11 | 2023-2024 | Vtama |
| Vyne Pharmaceuticals INC. | $889.30 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $796.13 | 2022-2025 | |
| Abbvie INC. | $767.65 | 2022-2025 | |
| Leo Pharma INC. | $692.31 | 2019-2025 | Adbry, Anzupgo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $654.04 | 2019-2025 | Cabtreo, Jublia, Duobrii |
| Almirall LLC | $593.20 | 2019-2025 | Klisyri |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eve Lupenko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.